Siponimod in the treatment of multiple sclerosis - a case study

Abstract

In the Czech Republic, siponimod is registered for the treatment of secondary progressive multiple sclerosis (SPMS). Siponimod is the first effective medicinal product for treating patients with SPMS, which favorably affects both clinical and magnetic resonance parameters.

An 18-year period of patient treatment for MS is presented.

Keywords

• siponimod
• SPMS
• multiple sclerosis